

## Special Issue

# New Technology for Vaccines and Vaccine-Preventable Diseases

### Message from the Guest Editor

As infectious diseases continue to evolve and new pathogens emerge, the need for innovative vaccine solutions has never been more pressing. Advances in vaccine technologies not only promise to address longstanding health challenges but also provide new strategies for preventing future pandemics. The integration of artificial intelligence, big data, and other digital technologies into vaccine research opens up unprecedented opportunities for understanding epidemiology, predicting disease outbreaks, and accelerating vaccine design.

- Innovative vaccine technologies: new vaccine platforms and vaccine delivery systems; vaccine efficacy and safety of new vaccines; and vaccines for newly recognized or re-emerging infectious diseases.
- Vaccine distribution and accessibility: improving global vaccine access.
- Immunology of vaccine responses: cellular and humoral immunity in new vaccines.
- Artificial intelligence and big data: applications in vaccine-preventable disease epidemiology, disease prediction, vaccine development, and understanding vaccine-induced immunity.

---

### Guest Editor

Dr. Jue Liu

Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China

---

### Deadline for manuscript submissions

20 October 2025



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/230725](https://mdpi.com/si/230725)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).